semaglutide
Semaglutide vs Tirzepatide - Will Pharmacy Budgets Fail?
Semaglutide vs Tirzepatide - Will Pharmacy Budgets Fail? In March 2026, the FDA removed semaglutide, tirzepatide, and liraglutide from the 503B bulk list, causing a 30% rise in administrative workload for community pharmacies. This change forces pharmacies to negotiate many more contracts and raises drug costs, putting pressure on budgets